IL318694A - Anti-ccr8 antibodies and methods of use - Google Patents

Anti-ccr8 antibodies and methods of use

Info

Publication number
IL318694A
IL318694A IL318694A IL31869425A IL318694A IL 318694 A IL318694 A IL 318694A IL 318694 A IL318694 A IL 318694A IL 31869425 A IL31869425 A IL 31869425A IL 318694 A IL318694 A IL 318694A
Authority
IL
Israel
Prior art keywords
methods
ccr8 antibodies
ccr8
antibodies
Prior art date
Application number
IL318694A
Other languages
Hebrew (he)
Inventor
Ming Fang
Liu Xue
Hanzi Sun
Xiaoyan Tang
Ming Jiang
Xitao Wang
Yun Chen
Chichi Huang
Wenjie Wang
Jing Zhang
Wenbo Jiang
Original Assignee
Beigene Switzerland Gmbh
Ming Fang
Liu Xue
Hanzi Sun
Xiaoyan Tang
Ming Jiang
Xitao Wang
Yun Chen
Chichi Huang
Wenjie Wang
Jing Zhang
Wenbo Jiang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Switzerland Gmbh, Ming Fang, Liu Xue, Hanzi Sun, Xiaoyan Tang, Ming Jiang, Xitao Wang, Yun Chen, Chichi Huang, Wenjie Wang, Jing Zhang, Wenbo Jiang filed Critical Beigene Switzerland Gmbh
Publication of IL318694A publication Critical patent/IL318694A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL318694A 2022-08-04 2023-08-04 Anti-ccr8 antibodies and methods of use IL318694A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2022110335 2022-08-04
PCT/CN2023/111215 WO2024027823A1 (en) 2022-08-04 2023-08-04 Anti-ccr8 antibodies and methods of use

Publications (1)

Publication Number Publication Date
IL318694A true IL318694A (en) 2025-03-01

Family

ID=89848548

Family Applications (1)

Application Number Title Priority Date Filing Date
IL318694A IL318694A (en) 2022-08-04 2023-08-04 Anti-ccr8 antibodies and methods of use

Country Status (13)

Country Link
US (1) US20250115671A1 (en)
EP (1) EP4565613A4 (en)
JP (1) JP2025525916A (en)
KR (1) KR20250044359A (en)
CN (1) CN119677778A (en)
AU (1) AU2023319869A1 (en)
CA (1) CA3263543A1 (en)
CL (1) CL2025000297A1 (en)
CO (1) CO2025002301A2 (en)
IL (1) IL318694A (en)
MX (1) MX2025001452A (en)
TW (1) TW202413426A (en)
WO (1) WO2024027823A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN122459678A (en) 2023-12-29 2026-07-24 百时美施贵宝公司 Combination therapy of KRAS inhibitors and Treg depletion agents
CN119080936B (en) * 2024-10-24 2025-05-23 百济神州(上海)生物科技有限公司 Anti-CCR 8 antibodies and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110835371A (en) * 2018-08-19 2020-02-25 普米斯生物技术(苏州)有限公司 Anti-CCR8 monoclonal antibody and its application
BR112021011431A2 (en) * 2018-12-27 2021-11-23 Univ Osaka Monoclonal antibody or an antibody fragment thereof that binds to ccr8, its use, as well as pharmaceutical composition, polynucleotide, expression vector and kit
AU2021205877B2 (en) * 2020-01-06 2024-06-20 Vaccinex, Inc. Anti-CCR8 antibodies and uses thereof
AU2021244200A1 (en) * 2020-03-23 2022-11-24 Bristol-Myers Squibb Company Anti-CCR8 antibodies for treating cancer
TW202216771A (en) * 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 Ccr8 antibodies for therapeutic applications
JP7610302B2 (en) * 2020-08-28 2025-01-08 ハーバー・バイオメド・(シャンハイ)・カンパニー・リミテッド CCR8 antibodies and uses thereof
AU2021277712B2 (en) * 2020-10-16 2023-05-25 LaNova Medicines Limited Anti-CCR8 monoclonal antibodies and uses thereof
JP2024531409A (en) * 2021-08-20 2024-08-29 ハイファイバイオ, インコーポレイテッド Anti-CCR8 Antibodies and Uses Thereof

Also Published As

Publication number Publication date
EP4565613A4 (en) 2026-05-27
MX2025001452A (en) 2025-03-07
EP4565613A1 (en) 2025-06-11
US20250115671A1 (en) 2025-04-10
TW202413426A (en) 2024-04-01
CO2025002301A2 (en) 2025-03-27
JP2025525916A (en) 2025-08-07
CA3263543A1 (en) 2024-02-08
AU2023319869A1 (en) 2025-02-20
CN119677778A (en) 2025-03-21
CL2025000297A1 (en) 2025-06-06
KR20250044359A (en) 2025-03-31
WO2024027823A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
GB202019709D0 (en) Anti-Coronavirus antibodies and methods of use
IL316368A (en) Anti-tl1a antibodies and methods of use thereof
PL4200018T3 (en) Anti-par-2 antibodies and methods of use thereof
IL315845A (en) Anti-dectin-1 antibodies and methods of use thereof
IL298668B1 (en) Anti-cd200r1 antibodies and methods of use thereof
IL319590A (en) Multispecific antibodies and methods of use thereof
IL286641B1 (en) Engineered iga antibodies and methods of use
IL316065A (en) Anti-cd28 antibodies and methods of use thereof
IL317690A (en) Anti-gpnmb antibodies and methods of use thereof
CA3266931A1 (en) Anti-napi2b antibodies and methods of use
CA3266793A1 (en) Anti-b7h3 antibodies and methods of use
CA3263543A1 (en) Anti-ccr8 antibodies and methods of use
IL308260A (en) Anti-tigit antibodies and methods of use thereof
IL316700A (en) Anti-bmp9 antibodies and methods of use thereof
IL311003A (en) Anti-her2 antibodies and methods of use thereof
IL321679A (en) Anti-ror-2 antibodies and methods of use
IL325937A (en) AAV-delivered antibodies and methods of using them
IL318357A (en) Anti- il27r antibodies and methods of use thereof
IL316894A (en) Anti-tnfr2 antibodies and methods of use thereof
IL310551A (en) Osmr-specific monoclonal antibodies and methods of their use
IL325837A (en) Bispecific PD-L1X4-1BB antibodies and methods of using them
IL325840A (en) Bispecific PD-L1XCD28 antibodies and methods of using them
AU2024374796A1 (en) Anti-migis-alpha antibodies and methods of use thereof
GB202204813D0 (en) Human monoclonal antibodies and methods of use thereof
GB202204736D0 (en) Human monoclonal antibodies and methods of use thereof